October 27, 2006
VANCOUVER, Canada— iCo Therapeutics Inc. announced today that Dr. David S. Boyer will join its strategic advisory team. As an ophthalmologist and senior partner of the Retina-Vitreous Associates Medical Group in California, Dr. Boyer specializes in diseases of the retina and vitreous. He is a Clinical Associate Professor of Ophthalmology at the University of Southern California and has worked on trials for age-related macular degeneration, diabetic retinopathy, and cytomegalovirus retinitis.
“We are pleased to have Dr. Boyer join our advisory team,” said Andrew Rae, iCoTherapeutics’ President and Chief Executive Officer. “His clinical knowledge and experience as an advisor to dynamic and successful biotechnology companies brings strength to our strategic advisory team.”
Dr. Boyer has served on the advisory boards for Alcon, Novartis, Eyetech/Pfizer, Genentech, Neurotech and the Macular Degeneration Partnership. He is a reviewer for several ophthalmology and diabetes medical publications including Archives of Ophthalmology, American Journal of Ophthalmology, Diabetes Care, and Ophthalmology.
Throughout his career, Dr. Boyer has been honoured by prestigious organizations including the American Academy of Ophthalmology (Board of Trustees Honor Award Certificate) and Retinitis Pigmentosa International (1996 Jules Stein Living Tribute Award). Every year since 2000, he has been selected by his peers to be listed in Best Doctors In America.
Dr. Boyer’s professional affiliations include the Los Angeles Medical Association, Los Angeles Eye Society, American Board of Ophthalmology, Discovery Fund for Eye Research, American Academy of Ophthalmology and Otolaryngology, California Medical Association, Vitreous Society, American Medical Association, Retinitis Pigmentosa International, and the American Diabetes Association. Dr. Boyer earned his medical degree at Chicago Medical School, completed his internship and residency at the USC/Los Angeles County Medical Center, and went on to do his fellowship in retinal surgery at the Wills Eye Hospital in Philadelphia.
About iCo Therapeutics, Inc.
iCo Therapeutics Inc. is an emerging, Vancouver-based biotechnology company focused on developing pre-existing drugs for a range of new conditions affecting isolated biological environments – areas such as the eye, spinal cord, or joints – where locally-administered application of these therapies would have minimal systemic distribution and fewer safety issues.
For more information, visit the company website at: https://icotherapeutics.com.
Business Development Contact:
Dr. John Clement, CTO
Mr. John Meekison, CFO